Kinda hard to make sense of the post you're replying to, unless hard facts and not dream-like projections and no FDA supported the share price conjectures.
It's always possible for the FDA or the EU to take positive SPA action regarding SMD, but that's hardly the catalyst, that would propel the share price up to those level.
Actually, I am of the feeling y the ned of the 2Q, that just the opposite in the share price has more potential for happening.
The keys, imo, are really obtaining adequate and constructive financing and starting Phase 2.
I refer to my post of yesterday,#84591 and the reply #84649. as possibly being a more relevant current assessment of what's happening with Ocata.
Firstly, for all intent and purposes, Ocata is a non-functioning company except for meeting items like payroll, rent, etc.
This board's assumptions are that this is currently being funded by declining company cash and Lincoln draws. Those days, let alone the ability to start phase 2, are severely restricted and in question and soon coming to an end.
The main challenge facing Ocata today, is clearly one of financing and clearly one of starting and insuring funds for Phase 2. Without these events happening, now at least 6 months behind schedule after a totally unsuccessful secondary in the marketplace at an acceptable price to Ocata, assumed to have been somewhere in the 6.00-7.00 range.
The company is desperate for financing, going nowhere without it and in a very weak bargaining/placement position we've clearly seen, which suggests desperate action.
The other event historically extremely unusual event, seemingly coming out of nowhere, especially at this time in the clinical progress of the company, is the apparent sale/placement of shares with institutional entities. History shows this is not something that happens, especially to this apparent degree at all, on Phase 1 results.
The conclusion that seems to make possible sense to me, is that the Ocata Board and Wotton, have decided to sell/place shares, enough shares at a greatly reduced share price from the current price, to accumulate enough capital to begin and remotely possibly fund an entire Phase 2.
This event under this possible scenario, will be communicated to us in the 2Q SEC document to shareholders dismay, I fear, but the company's on 'life support' and going nowhere further with the FDA without some move to shore up finances and regain some forward momentum.
